Journal of Cancer Research and Therapeutics

ORIGINAL ARTICLE
Year
: 2016  |  Volume : 12  |  Issue : 1  |  Page : 314--317

A pilot study to evaluate the efficacy of cerrobend shielding stents in preventing adverse radiotherapeutic effects in buccal carcinoma patients


Karma Yangchen1, Ramashanker Siddharth1, Saumyendra V Singh1, Raghuwar D Singh1, Himanshi Aggarwal1, Niraj Mishra1, Shuchi Tripathi1, Kirti Srivastava2, Teethraj Verma2, Pradeep Kumar1 
1 Department of Prosthodontics, Faculty of Dental Sciences, King George's Medical University UP, Uttar Pradesh, India
2 Department of Radiotherapy, King George's Medical University UP, Lucknow, Uttar Pradesh, India

Correspondence Address:
Saumyendra V Singh
2/273, Viram Khand, Gomti Nagar, Lucknow - 226 010, Uttar Pradesh
India

Background: Radiation stents made of Lipowitz metal or cerrobend alloy are commonly used to shield uninvolved tissues from electron beams used in therapeutic radiation treatment of head and neck cancers. However, studies investigating the efficacy of cerrobend shielding stent in patients with unilateral buccal carcinoma remain rare. Purpose: To evaluate the efficacy of cerrobend shielding stents in minimizing the potential adverse effects of radiation on oral tissues in buccal carcinoma patients. Materials and Methods: Twenty.eight participants were selected for the study based on predetermined inclusion criteria, out of which four participants were lost to follow-.up. Half of the remaining participants. (N = 12) were randomly given cerrobend shielding stent and the remaining 12 formed the control group. The effects of radiotherapy were evaluated by using Radiation Therapy Oncology Group. (RTOG) 0435 Head and Neck adverse effects grading tool. All participants were evaluated for xerostomia, mucositis, dysphagia, salivary changes, dysguesia, pain, trismus and radiation caries at baseline and 1 and 3. months post.radiotherapy. Results: All adverse effects were higher in control compared to study group, with post therapy difference for pain in swallowing, salivary changes, mucositis, dysphagia, dry mouth and caries being statistically significant. Conclusions: Cerrobend alloy can be used effectively as shielding stent to reduce the adverse effects associated with external beam radiation therapy in unilateral buccal carcinoma patients.


How to cite this article:
Yangchen K, Siddharth R, Singh SV, Singh RD, Aggarwal H, Mishra N, Tripathi S, Srivastava K, Verma T, Kumar P. A pilot study to evaluate the efficacy of cerrobend shielding stents in preventing adverse radiotherapeutic effects in buccal carcinoma patients.J Can Res Ther 2016;12:314-317


How to cite this URL:
Yangchen K, Siddharth R, Singh SV, Singh RD, Aggarwal H, Mishra N, Tripathi S, Srivastava K, Verma T, Kumar P. A pilot study to evaluate the efficacy of cerrobend shielding stents in preventing adverse radiotherapeutic effects in buccal carcinoma patients. J Can Res Ther [serial online] 2016 [cited 2020 Apr 10 ];12:314-317
Available from: http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2016;volume=12;issue=1;spage=314;epage=317;aulast=Yangchen;type=0